Helping projects
change the future
APPLY NOW

News

How can a venture fund assist in drug development?

20 August 2019

Primer Capital investment analyst Sofia Yartseva elaborated on the role of venture investments in drug development process and its further marketing.

How can a venture fund assist in drug development?

Primer Capital investment analyst Sofia Yartseva elaborated on the role of venture investments in drug development process and its further marketing.
 

Primer Capital ranked #1 among Biotech Venture Funds in Europe

12 August 2019

Primer Capital has been awarded the Best Biotech VC Fund – Europe by Wealth & Money Management Awards 2019.

Primer Capital ranked #1 among Biotech Venture Funds in Europe

Primer Capital has been awarded the Best Biotech VC Fund – Europe by Wealth & Money Management Awards 2019.
 

Portfolio unit's founder ranked among top 20 medtech entrepreneurs

10 July 2019

The founder of Data MATRIX (Primer Capital's portfolio project) entered the ranking of the top 20 most successful MedTech entrepreneurs according to RusBase. 

Portfolio unit's founder ranked among top 20 medtech entrepreneurs

The founder of Data MATRIX (Primer Capital's portfolio project) entered the ranking of the top 20 most successful MedTech entrepreneurs according to RusBase. 
 

Primer Capital Experts on Ethical Investment

5 July 2019

Anton Lavrentev, head of the legal department at Primer Capital, in his interview for VC.ru talked about ethical components which are essential for investors to consider before taking on new target. 

Primer Capital Experts on Ethical Investment

Anton Lavrentev, head of the legal department at Primer Capital, in his interview for VC.ru talked about ethical components which are essential for investors to consider before taking on new target. 
 

Case in point: Botkin AI analyzing CT scans for cancer detection

3 July 2019

Sergei Sorokin, the founder of Botkin AI project, a Primer Capital's portfolio unit, and an expert in IT solutions for medicine shared his views on AI within Russian healthcare system with HighTech

Case in point: Botkin AI analyzing CT scans for cancer detection

Sergei Sorokin, the founder of Botkin AI project, a Primer Capital's portfolio unit, and an expert in IT solutions for medicine shared his views on AI within Russian healthcare system with HighTech
 

Botkin.AI, an AI medical platform, raised 100 million rubles in investment

3 June 2019

Botkin.AI, Primer Capital’s portfolio unit, raised a round A of investments for the development of the artificial intelligence (AI) platform for cancer detection.

Botkin.AI, an AI medical platform, raised 100 million rubles in investment

Botkin.AI, Primer Capital’s portfolio unit, raised a round A of investments for the development of the artificial intelligence (AI) platform for cancer detection.
 

Head of Primer Capital to choose among the best pharmaceutical and medical projects

27 May 2019

Application period for the Startup Rally competition initiated by the Ministry of Industry and Trade of Russia ends June 1, 2019. Primer Capital COO Elizaveta Rozhdestvenskaya, as one of the judges, will be evaluating the projects of teams working on the development of new drugs, diagnostic test systems and medical products.

Head of Primer Capital to choose among the best pharmaceutical and medical projects

Application period for the Startup Rally competition initiated by the Ministry of Industry and Trade of Russia ends June 1, 2019. Primer Capital COO Elizaveta Rozhdestvenskaya, as one of the judges, will be evaluating the projects of teams working on the development of new drugs, diagnostic test systems and medical products.
 

Primer Capital Partners with an accelerator by AstraZeneca and Skolkovo

7 May 2019

Primer Capital, the leading Russian pharma and biotech venture fund, partnered with the acceleration program launched by AstraZeneca and Skolkovo Foundation.

Primer Capital Partners with an accelerator by AstraZeneca and Skolkovo

Primer Capital, the leading Russian pharma and biotech venture fund, partnered with the acceleration program launched by AstraZeneca and Skolkovo Foundation.
 

Survival course. Breakthrough development of cell products and technologies for target treatment of cancer

25 April 2019

New cell products and technologies breakthroughs for targeted cancer therapy can dramatically change therapy prognosis for thousands of patients.
On April 24, within the Skolkovo StartUp Tour 2019 in Novosibirsk, Primer Capital and the Novosibirsk innovation company ECAR signed an agreement with the intention to collaborate on the development of cellular therapy for the treatment of metastatic hormone-sensitive prostate cancer.

Survival course. Breakthrough development of cell products and technologies for target treatment of cancer

New cell products and technologies breakthroughs for targeted cancer therapy can dramatically change therapy prognosis for thousands of patients.
On April 24, within the Skolkovo StartUp Tour 2019 in Novosibirsk, Primer Capital and the Novosibirsk innovation company ECAR signed an agreement with the intention to collaborate on the development of cellular therapy for the treatment of metastatic hormone-sensitive prostate cancer.
 

Multiple myeloma drug developer has become a resident of the research lab space CoLaborator® by Bayer

19 April 2019

Hemofarm, a startup and the developer of a biotech drug for patients diagnosed with multiple myeloma and non-Hodgkin's lymphoma, has become a resident at the Bayer innovation research lab CoLabrator®.

Multiple myeloma drug developer has become a resident of the research lab space CoLaborator® by Bayer

Hemofarm, a startup and the developer of a biotech drug for patients diagnosed with multiple myeloma and non-Hodgkin's lymphoma, has become a resident at the Bayer innovation research lab CoLabrator®.

Записи 1 - 10 of 49
First | Prev. | 1 2 3 4 5 | Next | Last